Skip to main content

Advertisement

SpringerLink
Log in

Cardiovascular risk-benefit ratio of thiazolidinediones

  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

Abstract

The insulin-sensitizing thiazolidinediones (TZDs) are effective antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). Early research has suggested they hold promise for mitigating some of the negative cardiovascular implications of insulin resistance. Although these drugs, in addition to lowering glucose, improve lipid profiles, reduce blood pressure, enhance endothelial function, and appear to have a beneficial impact on various surrogates of atherosclerosis, their effect on actual cardiovascular outcomes is less clear. Importantly, any benefit on cardiovascular events may be offset to some degree by fluid retention and a small increased risk of heart failure. Possible differential clinical effects between the two available members of this class have further contributed to the debate. We review these issues in the context of the overall cardiovascular risk-benefit ratio of the TZDs in patients with T2DM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Buchanan T, Xiang A, Peters R, et al.: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002, 51:2796–2803.

    Article  PubMed  CAS  Google Scholar 

  2. Xiang A, Peters R, Kjos S, et al.: Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006, 55:517–522.

    Article  PubMed  CAS  Google Scholar 

  3. DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, et al.: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096–1105.

    Article  PubMed  CAS  Google Scholar 

  4. Defronzo R: Actos Now for Prevention of Diabetes (ACT NOW). Presented at the 68th Scientific Sessions of the American Diabetes Association. San Francisco; June 6–10, 2008.

  5. Kahn S, Haffner S, Heise M, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427–2443.

    Article  PubMed  CAS  Google Scholar 

  6. Targher G, Bertolini L, Poli F, et al.: Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005, 54:3541–3546.

    Article  PubMed  CAS  Google Scholar 

  7. Belfort R, Harrison S, Brown K, et al.: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297–2307.

    Article  PubMed  CAS  Google Scholar 

  8. Ratziu V, Giral P, Jacqueminet S, et al.: Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial. Gastroenterology 2008, 135:100–110.

    Article  PubMed  CAS  Google Scholar 

  9. Goldberg R, Kendall D, Deeg M, et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28:1547–1554.

    Article  PubMed  CAS  Google Scholar 

  10. Deeg M, Buse J, Goldberg R, et al.: Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007, 30:2458–2464.

    Article  PubMed  CAS  Google Scholar 

  11. Mazzone T, Meyer P, Feinstein S, et al.: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006, 296:2572–2581.

    Article  PubMed  CAS  Google Scholar 

  12. Koshiyama H, Shimono D, Kuwamura N, et al.: Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001, 86:3452–3456.

    Article  PubMed  CAS  Google Scholar 

  13. Langenfeld M, Forst T, Hohberg C, et al.: Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005, 111:2525–2531.

    Article  PubMed  CAS  Google Scholar 

  14. Minamikawa J, Tanaka S, Yamauchi M, et al.: Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998, 83:1818–1820.

    Article  PubMed  CAS  Google Scholar 

  15. Sidhu J, Kaposzta Z, Markus H, et al.: Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004, 24:930–934.

    Article  PubMed  CAS  Google Scholar 

  16. Hedblad B, Zambanini A, Nilsson P, et al.: Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. J Intern Med 2007, 261:293–305.

    Article  PubMed  CAS  Google Scholar 

  17. Nissen S, Nicholls S, Wolski K, et al.: Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008, 299:1561–1573.

    Article  PubMed  CAS  Google Scholar 

  18. Takagi T, Akasaka T, Yamamuro A, et al.: Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 2000, 36:1529–1535.

    Article  PubMed  CAS  Google Scholar 

  19. Takagi T, Yamamuro A, Tamita K, et al.: Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol 2002, 89:318–322.

    Article  PubMed  CAS  Google Scholar 

  20. Takagi T, Yamamuro A, Tamita K, et al.: Pioglitazone reduced neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003, 146:E5.

    Article  PubMed  Google Scholar 

  21. Marx N, Wohrle J, Nusser T, et al.: Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005, 112:2792–2798.

    Article  PubMed  CAS  Google Scholar 

  22. Choi D, Kim SK, Choi SH, et al.: Preventative effects of rosiglitazone on restentosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004, 27:2764–2766.

    Article  Google Scholar 

  23. Bertrand O: Vein-Coronary Atherosclerosis and Rosiglitazone After Bypass Surgery: VICTORY trial. Presented at the 57th Annual Scientific Session of the American College of Cardiology. Chicago; March 29–April 1, 2008.

  24. Inzucchi S, Masoudi F, Wang Y, et al.: Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 2005, 28:1680–1689.

    Article  PubMed  CAS  Google Scholar 

  25. Lipscombe L, Gomes T, Lévesque L, et al.: Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007, 298:2634–2643.

    Article  PubMed  CAS  Google Scholar 

  26. McAfee A, Koro C, Landon J, et al.: Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007, 16:711–725.

    Article  PubMed  Google Scholar 

  27. Gerrits C, Bhattacharya M, Manthena S, et al.: A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007, 16:1065–1071.

    Article  PubMed  Google Scholar 

  28. Dormandy J, Charbonnel B, Eckland D, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet 2005, 366:1279–1289.

    Article  PubMed  CAS  Google Scholar 

  29. Erdmann E, Dormandy JA, Charbonnel B, et al.: The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. J Am Coll Cardiol 2007, 49:1772–1780.

    Article  PubMed  CAS  Google Scholar 

  30. Wilcox R, Bousser MG, Betteridge DJ, et al.: Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (Prospective Pioglitazone Clinical Trial in Macrovascular Events 04). Stroke 2007, 38:e106.

    Article  Google Scholar 

  31. Nissen S, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457–2471.

    Article  PubMed  CAS  Google Scholar 

  32. Diamond G, Bax L, Kaul S: Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007, 147:578–581.

    PubMed  Google Scholar 

  33. Home P, Pocock S, Beck-Nielsen H, et al.: Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med 2007, 357:28–38.

    Article  PubMed  CAS  Google Scholar 

  34. Singh S, Loke Y, Furberg C: Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007, 298:1189–1195.

    Article  PubMed  CAS  Google Scholar 

  35. Lincoff A, Wolski K, Nicholls S, et al.: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180–1188.

    Article  PubMed  CAS  Google Scholar 

  36. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545–2559.

    Article  PubMed  CAS  Google Scholar 

  37. Abraira C: The VA Diabetes Trial of Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT). Presented at the 68th Scientific Sessions of the American Diabetes Association. San Francisco; June 6–10, 2008.

  38. Erdmann E, Charbonnel B, Wilcox R, et al.: Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007, 30:2773–2778.

    Article  PubMed  CAS  Google Scholar 

  39. Lago R, Singh P, Nesto R: Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007, 370:1129–1136.

    Article  PubMed  CAS  Google Scholar 

  40. Giles T, Miller A, Elkayam U, et al.: Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail 2008, 14:445–452.

    Article  PubMed  CAS  Google Scholar 

  41. Masoudi F, Inzucchi S, Wang Y, et al.: Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005, 111:583–590.

    Article  PubMed  CAS  Google Scholar 

  42. Dargie H, Hildebrandt P, Riegger G, et al.: A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol 2007, 49:1696–1704.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 333 Cedar Street, LLCI 101, PO Box 208020, New Haven, CT, 06520, USA

    Kasia Lipska

Authors
  1. Kasia Lipska
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Silvio E. Inzucchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kasia Lipska.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lipska, K., Inzucchi, S.E. Cardiovascular risk-benefit ratio of thiazolidinediones. Curr Cardio Risk Rep 3, 42–50 (2009). https://doi.org/10.1007/s12170-009-0008-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12170-009-0008-9

Keywords

Search

Navigation